Related Experiment Video
Updated: Nov 2, 2025
Development of a Refined Protocol for Trans-scleral Subretinal Transplantation of Human Retinal Pigment Epithelial Cells into Rat Eyes
Published on: August 12, 2017
Topical Erythropoietin for Treatment of Scleral Necrosis
Sepehr Feizi1, Mohammadhasan Alemzadeh-Ansari1, Alireza Baradaran-Rafii1
1Ophthalmic Research Center, Department of Ophthalmology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Purpose:
To investigate the safety and efficacy of topical erythropoietin for the treatment of scleral necrosis.
Methods:
This study enrolled eight consecutive patients with scleral necrosis due to previous ocular surgery, rheumatoid arthritis-associated necrotizing anterior scleritis, and thermal and chemical burns. Conventional treatments failed to heal avascular scleral lesions in all eyes. Patients were treated with topical erythropoietin (3000 IU/mL) four times a day.
Results:
The mean patient age was 37.6 ± 15.5 years. The interval between the development of scleral necrosis and initiation of topical erythropoietin was 25.6 ± 12.0 days. The necrotic sclera completely healed within 31.9 ± 16.9 days in all patients. The avascular lesions did not recur, and there was no evidence of side effects during the study.
Conclusion:
Our results showed that topical erythropoietin could be safely used to manage scleral necrosis. Randomized clinical trials are needed to further explore the efficacy of this intervention in patients with avascular scleral lesions.
More Related Videos
11:03Subretinal Transplantation of Human Embryonic Stem Cell Derived-retinal Pigment Epithelial Cells into a Large-eyed Model of Geographic Atrophy
Published on: January 22, 2018
11:20Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
Published on: June 14, 2021
Related Concept Videos
01:19Clinical Applications of Epidermal Stem Cells
01:14Erythropoiesis